PT  - JOURNAL ARTICLE
AU  - Bi, Qifang
AU  - Dickerman, Barbra A.
AU  - Nguyen, Huong Q.
AU  - Martin, Emily T.
AU  - Gaglani, Manjusha
AU  - Wernli, Karen J.
AU  - Balasubramani, G.K.
AU  - Flannery, Brendan
AU  - Lipsitch, Marc
AU  - Cobey, Sarah
AU - the US Flu Vaccine Effectiveness Network Investigators
TI  - Reduced effectiveness of repeat influenza vaccination: distinguishing among within-season waning, recent clinical infection, and subclinical infection
AID  - 10.1101/2023.03.12.23287173
DP  - 2024 Jan 01
TA  - medRxiv
PG  - 2023.03.12.23287173
4099  - http://medrxiv.org/content/early/2024/04/10/2023.03.12.23287173.short
4100  - http://medrxiv.org/content/early/2024/04/10/2023.03.12.23287173.full
AB  - Studies have reported that prior-season influenza vaccination is associated with higher risk of clinical influenza infection among vaccinees. This effect might arise from incomplete consideration of within-season waning and recent infection. Using data from the US Flu Vaccine Effectiveness (VE) Network (2011-2012 to 2018-2019 seasons), we found that repeat vaccinees were vaccinated earlier in a season by one week. After accounting for waning VE, repeat vaccinees were still more likely to test positive for A(H3N2) (OR=1.11, 95%CI:1.02-1.21) but not for influenza B or A(H1N1). We found that clinical infection influenced individuals’ decision to vaccinate in the following season while protecting against clinical infection of the same (sub)type. However, adjusting for recent clinical infections did not strongly influence the estimated effect of prior-season vaccination. In contrast, we found that adjusting for subclinical infection could theoretically attenuate this effect. Additional investigation is needed to determine the impact of subclinical infections on VE.Summary of main points: Two potential factors, timing of vaccination and clinical infection history, cannot fully explain the increased influenza infection risk in repeat vaccinees compared with non-repeat vaccinees. Subclinical infection in the previous season may explain the effect.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was partially supported by the Collaborative Influenza Vaccine Innovation Centers (CIVICs) contract 75N93019C00051 (S.C. and Q.B.). ML acknowledges support from US NIH grant 1R01GM139926 to University of Michigan. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee of the University of Chicago gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesData and relevant code are available at https://github.com/cobeylab/FluVE_repeatvac_public